Literature DB >> 15464148

Evolving perspectives on neurobiological research on the addictions: celebration of the 30th anniversary of NIDA.

Mary Jeanne Kreek1, Stefan D Schlussman, Gavin Bart, K Steven Laforge, Eduardo R Butelman.   

Abstract

The roots of the Laboratory of the Biology of the Addictive Diseases are in the development of methadone maintenance for the treatment of opiate addiction. Methadone maintenance therapy continues to be one of the major effective forms of addiction pharmacotherapy and underscores the importance of biological factors in the physiology and treatment of the addictive diseases. Recent work in the Laboratory has focused on the neurobiological, neurochemical, neuroendocrine and behavioral aspects of addictive diseases (principally cocaine and the opiate addictions), using an interdisciplinary approach. The models we have focused on range from in vitro molecular biology and neuroscience, to in vivo animal models, to experiments in normal human populations and patients with specific addictive diseases, and most recently to the human molecular genetics of different addictive diseases. Two long-term corollary hypotheses have guided the Laboratory's work: (1) That the endogenous opioid peptide/receptor systems play a central role in the addictive states and therefore in their treatment. (2) That atypical responsivity to stressors (e.g., in the hypothalamic-pituitary-adrenal axis) plays a role in vulnerability and relapse to specific addictive diseases. This atypical responsivity may be drug-induced, environmentally acquired, and/or due to genetic variation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15464148     DOI: 10.1016/j.neuropharm.2004.07.024

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  9 in total

Review 1.  Stress, dysregulation of drug reward pathways, and the transition to drug dependence.

Authors:  George Koob; Mary Jeanne Kreek
Journal:  Am J Psychiatry       Date:  2007-08       Impact factor: 18.112

Review 2.  Role of a functional human gene polymorphism in stress responsivity and addictions.

Authors:  M J Kreek
Journal:  Clin Pharmacol Ther       Date:  2008-03-05       Impact factor: 6.875

3.  Gene expression profiling following short-term and long-term morphine exposure in mice uncovers genes involved in food intake.

Authors:  A Anghel; C A M Jamieson; X Ren; J Young; R Porche; E Ozigbo; D E Ghods; M L Lee; Y Liu; K Lutfy; T C Friedman
Journal:  Neuroscience       Date:  2010-02-06       Impact factor: 3.590

4.  Pharmacotherapy in the treatment of addiction: methadone.

Authors:  Mary Jeanne Kreek; Lisa Borg; Elizabeth Ducat; Brenda Ray
Journal:  J Addict Dis       Date:  2010-04

Review 5.  Progress in agonist therapy for substance use disorders: Lessons learned from methadone and buprenorphine.

Authors:  Chloe J Jordan; Jianjing Cao; Amy Hauck Newman; Zheng-Xiong Xi
Journal:  Neuropharmacology       Date:  2019-04-19       Impact factor: 5.250

6.  Subcellular plasticity of the corticotropin-releasing factor receptor in dendrites of the mouse bed nucleus of the stria terminalis following chronic opiate exposure.

Authors:  A Jaferi; D A Lane; V M Pickel
Journal:  Neuroscience       Date:  2009-06-17       Impact factor: 3.590

Review 7.  Drug-induced and genetic alterations in stress-responsive systems: Implications for specific addictive diseases.

Authors:  Yan Zhou; Dmitri Proudnikov; Vadim Yuferov; Mary Jeanne Kreek
Journal:  Brain Res       Date:  2009-11-12       Impact factor: 3.252

Review 8.  Bidirectional translational research: Progress in understanding addictive diseases.

Authors:  M J Kreek; S D Schlussman; B Reed; Y Zhang; D A Nielsen; O Levran; Y Zhou; E R Butelman
Journal:  Neuropharmacology       Date:  2008-08-07       Impact factor: 5.250

Review 9.  Opioids, dopamine, stress, and the addictions.

Authors:  Mary Jeanne Kreek
Journal:  Dialogues Clin Neurosci       Date:  2007       Impact factor: 5.986

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.